<u>Claim 1</u> (Currently Amended). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that includes Amphotericin B, wherein the Amphotericin B compound is present in an amount greater than about 92 96% with no greater than about 8 4% of impurity products, and a pharmaceutically effective carrier; and

administering a therapeutically effective amount of said composition to a subject in need thereof.

Claim 2 (Canceled).

<u>Claim 3</u> (Previously Presented). The method of claim 1, wherein the amphotericin B is present in an amount greater than about 98% and no greater than about 2% of impurity products.

<u>Claim 4</u> (Original). The method of claim 1, wherein said pharmaceutically acceptable carrier is a lipid carrier.

<u>Claim 5</u> (Original). The method of claim 1, wherein the administering step is intravenous.

<u>Claim 6</u> (Currently Amended). A pharmaceutical composition, comprising:

an active ingredient that has at least 92 96% of an amphotericin B compound and no greater than 8 4% of impurity products, and a pharmaceutically acceptable carrier.

Claim 7 (Canceled).

<u>Claim 8</u> (Previously Presented). The composition of claim 6, wherein the amphotericin B compound is present in an amount greater than about 98%.

Claims 9-16 (canceled).

<u>Claim 17</u> (Previously Presented). The method of claim 1, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

<u>Claim 18</u> (Previously Presented). The composition of claim 6, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

<u>Claim 19</u> (Previously Presented). A pharmaceutical composition that comprises:

an active ingredient that is at least 96% w/w of a compound of the following formula:

and a pharmaceutically acceptable carrier.

<u>Claim 20</u> (Previously Presented). The composition of claim 19, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 21 (Previously Presented). The composition of claim 19, the active ingredient comprising no greater than 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound.

<u>Claim 22</u> (Currently Amended). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that has at least 92 96% amphotericin B polyene compound and a pharmaceutically effective carrier; and

administering a therapeutically effective amount of said composition to a subject in need thereof.

Claim 23 (Previously Presented). The method of claim 22, wherein the active ingredient that is at least 96% w/w of a compound of the following formula:

and a pharmaceutically acceptable carrier.
Claim 24 (Previously Presented). The method of claim 22, wherein said pharmaceutically
acceptable carrier is a lipid carrier.
Claim 25 (Canceled).
Claim 26 (Canceled).
Claim 27 (Currently Amended). A pharmaceutical composition that comprises:
an active ingredient that is at least 92 96% w/w of a compound of the following formula